Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. President and director Adam David Sachs reported an open-market sale of 942 shares of Class A Common Stock on February 20, 2026, at a weighted average price of $2.0878 per share. After this transaction, he held 46,943 shares directly.
The sale was executed under a mandated “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units granted on May 19, 2022, and did not represent a discretionary trade by Sachs.
Vicarious Surgical Inc. director and Chief Technology Officer Sammy Khalifa reported an open-market sale of 754 shares of Class A common stock. The shares were sold at a weighted average price of $2.0841 per share, leaving 32,869 shares of Class A common stock held directly after the transaction.
According to the disclosure, this sale was executed solely to cover tax withholding obligations related to the vesting of restricted stock units granted on May 19, 2022, under the company’s equity incentive plan. The filing notes this was a mandated “sell to cover” transaction and not a discretionary trade by the reporting person.
Vicarious Surgical Inc. filing a Rule 144 notice that lists the proposed sale of 1,902 shares of Class A common stock following a 02/19/2026 restricted stock lapse. The broker shown is UBS Financial Services with a filing date of 02/20/2026.
The filing also reports prior sales of 239 shares on 12/03/2025 by Sammy Khalifa. The notice records standard transaction details for an insider sale under Rule 144.
Vicarious Surgical Inc. filed a Rule 144 notice indicating proposed sales of Class A common stock. The filing lists 2,377 shares tied to a restricted stock lapse on 02/19/2026. It also records a prior sale of 463 shares on 12/03/2025 by Adam Sachs.
Vicarious Surgical Inc. filed an 8-K describing updated severance and change in control protections for its Chief Executive Officer and Chief Financial Officer. CEO Stephen From received an amendment to his employment agreement that provides severance if he is terminated without cause or resigns for good reason, including enhanced cash payments, continued COBRA health premiums and full vesting of time-based equity if the termination occurs in connection with a change in control.
CFO Sarah Romano entered into a new Executive Severance and Change in Control Agreement with similar protections, scaled to her role. Her agreement also offers higher severance multiples, extended COBRA coverage and full vesting of time-based equity awards if a qualifying termination occurs within a defined window around a change in control. Both arrangements require signing a separation agreement with a release and restrictive covenants.
Vicarious Surgical Inc. reported the results of a special stockholder meeting held on January 9, 2026. Stockholders voted on a single proposal related to warrants previously issued by the company.
Holders of Class A and Class B common stock, voting together as a single class, approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock. The proposal passed with 14,991,093 votes in favor, 23,052 votes against, and 2,894 abstentions.
There were 2,591,229 shares of Class A and Class B common stock present or represented by proxy at the meeting, representing approximately 78.18% of the outstanding total voting power entitled to vote, which was sufficient to constitute a quorum.
Vicarious Surgical Inc. is offering up to $3,000,000 of Class A common stock through an at-the-market program under an existing $100,000,000 shelf registration. The shares will be sold from time to time on the New York Stock Exchange or other U.S. trading markets through H.C. Wainwright & Co. as sales agent or principal, earning a 3.0% commission on gross proceeds. Based on a recent NYSE price of $2.17, this would represent up to 1,382,488 shares, with total Class A shares outstanding potentially rising to 7,845,739, though actual issuance will depend on future trading prices and sale decisions.
The company plans to use any net proceeds for general corporate purposes, including working capital, capital spending, and research and development or clinical trial costs, and may also fund possible acquisitions or strategic investments. Vicarious Surgical is developing a single-port robotic surgical system that has not yet been authorized by the FDA and remains in a pre-commercial, development-focused stage. The company has an NYSE compliance plan in place after previously falling below market capitalization and equity listing thresholds, and warns that investors face significant risks, including dilution and share price volatility.
Vicarious Surgical Inc. is having its warrants removed from listing and registration on the New York Stock Exchange under Section 12(b) of the Securities Exchange Act of 1934. The notification is made on SEC Form 25, with the Exchange certifying it has reasonable grounds to file.
The affected security is described as warrants, with each whole warrant exercisable for 1/30th of a share of Class A common stock at an exercise price of $345.00. The New York Stock Exchange states it has complied with its rules to strike this class of securities, and that the issuer has complied with exchange and SEC requirements for the voluntary withdrawal of this class from listing and registration.
Vicarious Surgical Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., allowing the company to sell shares of its Class A common stock from time to time through the sales agent, subject to a new Form S-3 shelf registration statement becoming effective. The ATM prospectus supplement currently permits sales of shares with an aggregate market value of $2,286,052, based on the limitations of General Instruction I.B.6 of Form S-3.
The company will pay Wainwright a 3.0% commission on gross proceeds, plus specified fees and expenses, and can set parameters such as timing, daily limits, and minimum prices for any share sales. Separately, the NYSE has begun proceedings to delist and has immediately suspended trading in Vicarious Surgical’s publicly traded warrants (symbol “RBOT.WS”) due to “abnormally low” trading price levels, and the company does not intend to appeal. The Class A common stock will continue trading on the NYSE under “RBOT,” but its continued listing depends on regaining compliance with NYSE Section 802.01B by October 10, 2026. The company also issued a press release announcing guidance for anticipated cash burn for fiscal year 2026.